FibroBiologics Doses First Patients in Phase 1/2 Trial for Diabetic Foot Ulcer Treatment
Event summary
- First patients dosed in Phase 1/2 trial of CYWC628 for diabetic foot ulcers during the week of June 1, 2026.
- Second GMP manufacturing run of CYWC628 completed and scheduled for shipment to Australia during the week of June 15, 2026.
- First two batches of third GMP manufacturing run also completed.
- Trial is a prospective, multicenter, randomized study evaluating safety, tolerability, and efficacy of CYWC628.
The big picture
FibroBiologics' advancement in dosing patients for its Phase 1/2 trial of CYWC628 underscores the growing focus on fibroblast-based therapies for chronic wound healing. The parallel progress in manufacturing highlights the company's strategic push to balance clinical development with scalable production, a critical factor in the competitive landscape of regenerative medicine. With 270+ patents, FibroBiologics is positioning itself as a key player in leveraging cell therapy for multiple chronic diseases, including diabetic foot ulcers, a condition affecting millions globally.
What we're watching
- Clinical Progress
- How the initial dosing results will impact the pace of subsequent trial phases and regulatory interactions.
- Manufacturing Scale
- Whether FibroBiologics can sustain consistent GMP production to support expanding clinical demand.
- Market Differentiation
- The potential of CYWC628 to outperform existing treatments for diabetic foot ulcers in efficacy and safety.
Related topics